Print

TetraLogic Pharmaceuticals Announces Presentation on Smac Mimetic Birinapant at American Society of Hematology Annual Meeting  
12/10/2012 9:44:31 AM

MALVERN, Pa.--(BUSINESS WIRE)--TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced the poster presentation of preclinical data on its Smac mimetic drug candidate birinapant at the 54th ASH Annual Meeting and Exposition in Atlanta, Georgia. Birinapant has entered Phase 2 clinical trials for several solid tumors and a Phase 1/2 study in acute myeloid leukemia (AML) is ongoing.
//-->